Introduction
============

The intervertebral disc (IVD) comprises hydrated and gelatinous nucleus pulposus (NP) core, surrounding multilaminar annulus fibrosus, and cartilaginous endplates \[[@b1-asj-2018-0257]\]. IVD degeneration correlates with genetic, aging, and traumatic effects, causing different spinal disorders that are leading causes of chronic low back pain and high health costs \[[@b2-asj-2018-0257]\]. The extracellular matrix (ECM) of NP comprises water, proteoglycans, and collagen that provide bearing capacity of IVD to resist the mechanical load \[[@b3-asj-2018-0257]\]. The pathophysiological evidence demonstrates that IVD degeneration initiates from the NP, where the contents of *collagen type II* (*Col2*) and proteoglycan reduce with an abnormally increasing synthesis in *collagen type I* (*Col1*) \[[@b4-asj-2018-0257]\]. As the NP loses the cellularity and matrix integrity and becomes fibrotic, the process becomes irreversible. The degenerated IVD cannot transmit intervertebral forces optimally, and various degenerative processes occur subsequently.

At present, no cure exists for IVD degeneration. Thus, cell-based interventions for tissue regeneration in the early stages of degeneration could theoretically delay or even reverse the degenerative process and, perhaps, restore the biological and mechanical function of IVD. One potential cell-based therapy is the transplantation of autologous IVD cells \[[@b5-asj-2018-0257],[@b6-asj-2018-0257]\]. Clinically, the most applicable source of cells is surgically harvested IVD tissue to treat lumbar disc herniation and degenerative disc disease; however, these cells could display potentially pathological changes with a phenotype of cellular senescence \[[@b7-asj-2018-0257]\]. Alternatively, the overexpression of catabolic cytokines and degenerative enzymes \[[@b8-asj-2018-0257]\], as well as the declined production of matrix components, has also been reported in isolated NP cells \[[@b9-asj-2018-0257]\]. Moreover, using autologous NP cells harvested from adjacent healthy IVDs is unfeasible; however, this approach could initiate donor IVDs degeneration \[[@b10-asj-2018-0257]\]. Furthermore, restricted availability and suboptimal regenerative potential are major concerns to autologous differentiated NP cells \[[@b11-asj-2018-0257]\].

Recently, uncommitted mesenchymal stem cells (MSCs) have garnered special attention in cell-based therapy for IVD degeneration. Reportedly, the use of autologous MSCs could alleviate the lack of autologous grafts, possible donor-site morbidity, allogeneic immunogenicity, and potential infection transmissions of xenogeneic cells \[[@b12-asj-2018-0257]\]. To date, several approaches have been tested, including transplanting MSCs into IVDs \[[@b13-asj-2018-0257],[@b14-asj-2018-0257]\], coculturing MSCs and IVD cells \[[@b15-asj-2018-0257],[@b16-asj-2018-0257]\], and differentiating MSCs toward NP-like cells by various growth factors \[[@b14-asj-2018-0257],[@b17-asj-2018-0257]\]. Transforming growth factor-beta1 (TGF-β1) could induce MSCs differentiate into NP-like cells \[[@b17-asj-2018-0257],[@b18-asj-2018-0257]\]. However, we previously reported that TGF-β1-treated MSCs displayed an enhanced synthesis of both *Col2* and *Col1* \[[@b16-asj-2018-0257]\]. The overexpression of *Col1* signifies the fibrotic characteristics of the regenerated matrix that should be further enhanced for the NP regeneration. Statins, highly effective drugs to lower cholesterol levels, are extensively used to decrease the coronary artery disease-related morbidity \[[@b19-asj-2018-0257]\]. Studies have reported statins to stimulate the *bone morphogenetic protein-2* (*BMP-2*) expression and promote the expression of chondrogenic phenotype in rat chondrocytes as well as IVD cells \[[@b20-asj-2018-0257],[@b21-asj-2018-0257]\]. In an *in vitro* study, we revealed that lovastatin upregulated genes encoding *Col2*, *BMP-2*, and transcription factor *SOX9* in human degenerative NP cells, whereas the *Col1* expression was suppressed \[[@b22-asj-2018-0257]\]. The subsequent animal study illustrated that the intradiscal administration of lovastatin solution enhanced *BMP-2* and *SOX9* expressions and promoted chondrogenesis of rat caudal discs after the discography-simulated procedure \[[@b23-asj-2018-0257],[@b24-asj-2018-0257]\]. Per the chondrogenic effects of *BMP-2* and *SOX9*, lovastatin could induce the differentiation of MSCs into NP-like cells.

Hence, this study aims to examine the differences between the effects of TGF-β1 and lovastatin on the differentiation of MSCs toward the NP-like cell phenotype. Different settings including exceptional, simultaneous, or sequential treatments with TGF-β1 or lovastatin were tested.

Materials and Methods
=====================

We expanded commercially available human MSCs (Poietics; Lonza, Basel, Switzerland) as monolayers in tissue culture flasks in 5% CO~2~ at 37°C in the MSC medium (Lonza) for later use of experiments. To mimic the native microenvironment of NP cells, all MSC cultivations were conducted in a hypoxia working station (US Autoflow NU-4950; NuAire, Plymouth, MN, USA) with a mixture of 5% O~2~, 5% CO~2~, and 91.5% N2; this O~2~ concentration fulfills the requirements for a hypoxic culture that does not consume large amounts of nitrogen \[[@b25-asj-2018-0257]\]. The basal growth medium for the following experiments was DMEM/F-12 medium containing 10% fetal bovine serum (Gibco; Life Technologies, Grand Island, NY, USA), 100 nM dexamethasone, 50 U/mL penicillin, 50 mg/mL streptomycin, 100 mg/mL neomycin (Sigma-Aldrich, St. Louis, MO, USA), and 25 mg/mL L-ascorbic acid (SigmaAldrich).

1. Quantitative real-time polymerase chain reaction
---------------------------------------------------

Upon reaching 80% confluence, one of the four proposed treatments was given to the MSCs. As the TGF-β1 stimulation in the first 3 days of culture is crucial for MSCs to express a chondrogenic phenotype \[[@b26-asj-2018-0257]\], we treated MSCs with TGF-β1 for 72 hours in TGF-β--treated groups as follows: (1) group T: 10 ng/mL TGF-β1 (PeproTech, Rocky Hill, NJ, USA) for 72 hours; (2) group L: 5 mM lovastatin (Sigma-Aldrich) for 72 hours (according to our previous study \[[@b23-asj-2018-0257]\]): (3) group T+L: simultaneous treatment with 10 ng/mL TGF-β1 and 5 mM lovastatin for 72 hours; and (4) group T/L: sequential treatment with 10 ng/mL TGF-β1 for 72 hours then 5 mM lovastatin for 72 hours.

Then, RNA was extracted using a PureLink Mini RNA kit (Invitrogen, Carlsbad, CA, USA). During the extraction process, the RNA was treated with RNase-free DNase (Qiagen, Chatsworth, CA, USA) to eliminate the influence of DNA on the reverse transcription polymerase chain reaction (PCR). The RNA content was determined with a spectrophotometer (NanoDrop 2000 UV-Vis Spectrophotometer; Thermo Fisher Scientific, Waltham, MA, USA) at OD~260~. The complement DNA was synthesized from the extracted RNA using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). DNA synthesized from 20 ng of RNA was used for each PCR primer. To reverse transcribe the RNA, we used random hexamers from the TaqMan RT Reagents and RT reaction mix (Applied Biosystems). For the PCR step, TaqMan Universal PCR Master Mix and Assays-on-Demand Gene Expression probes (ABI PRISM 7900HT Fast Real-Time PCR System, Applied Biosystems) were used. Genes examined included those for *glyceraldehydes-3-phosphate dehydrogenase* (*GAPDH*), *aggrecan* (*AGC*), *Col1*, *Col2*, *SOX9*, *matrix metalloproteinase (MMP)-13*, and *BMP-2*. Relative expressions were calculated by using 2^--∆∆CT^, where CT is the cycle threshold. Of note, the RNA expression of each target gene was normalized to that of the housekeeping gene *GAPDH*. Then, DCT was evaluated by subtracting CT for *GAPDH* from CT for each target gene. The relative expression of each target gene was evaluated using the expression of 2^--∆∆CT^ by paired comparison of DCT values obtained from MSCs treated with 10 ng/mL TGF-β1. Notably, expressions of target genes were evaluated 6 times in each group.

2. Histological and immunohistochemical studies
-----------------------------------------------

MSCs (4×10^3^) were seeded into a well of a 48-well glass chamber slide (Nunc Lab-Tek II, Thermo Fisher Scientific) and then cultivated with proposed treatment regimens for 2 weeks: (1) group T: 10 ng/mL TGF-β1 (PeproTech); (2) group L: 5 mM lovastatin (Sigma-Aldrich); (3) group T+L: simultaneous treatment with 10 ng/mL TGF-β1 and 5 mM lovastatin; and (4) group T/L: sequential treatment with 10 ng/mL TGF-β1 for 72 hours then 5 mM lovastatin for 11 days.

After 2-week cultivation, chamber slides were fixed with 10% neutral buffered formaldehyde solution (Sigma-Aldrich) and prepared for histological inspections. The cells were stained with hematoxylin and eosin for examination of microscopic morphology.

For the immunohistochemical staining, chamber slides were immersed in a solution of methanol with 3% H~2~O~2~ for 10 minutes to quench the endogenous peroxidase activity and then incubated in a serum-blocking solution for 30 minutes to block nonspecific binding. Next, the cells were labeled with streptavidin--biotin (85-8943, Histostain-Plus; Invitrogen), followed by overnight incubation of the slides with primary antibody against *AGC*, *Col2*, or S-100 protein (Abcam, Cambridge, MA, USA). The presence of antigens was detected by a brown color after staining with 3,30-diaminobenzidine (Invitrogen). All cells were further counterstained with hematoxylin. Finally, negative controls were sectioned and subjected to identical staining procedure; however, the first antibody was replaced by isotype immunoglobulin G.

3. Statistical analysis
-----------------------

In this study, data obtained from each group are expressed as mean±standard error. Analysis of variance with posthoc Dunnett's multiple comparison tests was used to analyze the differences among groups. A difference of *p*\<0.05 was considered as statistically significant.

Results
=======

1. The mRNA expression of mesenchymal stem cells
------------------------------------------------

[Fig. 1](#f1-asj-2018-0257){ref-type="fig"} shows the relative expression levels of *AGC*, *Col1*, *Col2*, *SOX9*, and *MMP-13* genes in each group. Lovastatin-treated MSCs exhibited the highest *AGC* expression (4.483±0.381-fold) and the lowest *Col1* expression (0.119±0.005-fold) among groups (*p*\<0.01). Otherwise, no significant difference was noted in the mRNA expression for *AGC* and *Col1* among the T, T+L, and T/L groups. However, *Col2* and *SOX9* expressions were highest in the T/L group (1.968±0.408-fold and 1.414±0.212- fold, respectively), followed by the lovastatin group (1.510±0.397-fold and 1.212±0.039-fold, respectively). All three groups with lovastatin treatment exhibited significantly lower expression levels of MMP-13 compared with the group treated with TGF-β1 exclusively (*p*\<0.01). [Fig. 2](#f2-asj-2018-0257){ref-type="fig"} presents the relative expression levels of *BMP-2* genes in each group. *BMP-2* expression was significantly higher in all three groups with lovastatin treatment (group L, 10.214±1.169-fold; group T+L, 25.275±2.682-fold; group T/L, 24.350±1.742-fold), and the T+L and T/L groups exhibited a significantly higher *BMP-2* expression than that of the L group (*p*\<0.05).

2. Hematoxylin--eosin staining
------------------------------

In this study, TGF-β1--treated MSCs displayed a cobblestone-like shape, a high nuclear--cytoplasmic ratio, and a relatively higher cell density compared with other groups ([Fig. 3](#f3-asj-2018-0257){ref-type="fig"}). In addition, the T/L group exhibited a high cell density, whereas cells in the L, T+L, and T/L groups displayed a marginally extending cytoplasm.

3. Immunohistochemical study
----------------------------

All treated MSCs were positive to the immunohistochemical staining against *AGC* ([Fig. 4](#f4-asj-2018-0257){ref-type="fig"}) and *Col2* ([Fig. 5](#f5-asj-2018-0257){ref-type="fig"}), whereas the staining to S-100 protein was relatively weak ([Fig. 6](#f6-asj-2018-0257){ref-type="fig"}). However, TGF-β1--treated cells also produced *AGC* and *Col2* weakly. In addition, we found more pronounced staining of *AGC* ([Fig. 4](#f4-asj-2018-0257){ref-type="fig"}) and *Col2* ([Fig. 5](#f5-asj-2018-0257){ref-type="fig"}) in lovastatintreated groups. Furthermore, the T+L group had relatively stronger *AGC* and *Col2* staining relative to the T/L group.

Discussion
==========

Cell-based therapy offers a cure to regenerated IVDs, and a reliable cell source plays a vital role in this approach. Compared with unhealthy NP cells isolated from surgically excised IVD tissues, autologous MSCs serve as an alternative cell source. Although TGF-β is used to differentiate MSCs into NP-like cells, the high expression of *Col1* in these cells needs improvement \[[@b16-asj-2018-0257]-[@b18-asj-2018-0257]\]. Statins, a traditional class of drugs used to treat hypercholesterolemia, decrease the coronary artery disease-related morbidity \[[@b19-asj-2018-0257]\]. Besides the cardioprotective effects, statins reportedly maintain NP cells, a functional phenotype, and enhance ECM synthesis in rats \[[@b21-asj-2018-0257]-[@b23-asj-2018-0257]\]. Hence, we proposed that statins could improve NP-like cells induction and be useful in IVD regeneration.

A study reported that statins could suppress the nuclear factor-kB and mitogen-activated protein kinase pathways to inhibit cell apoptosis and matrix degradation in NP cells \[[@b22-asj-2018-0257]\]. In addition, our *in vitro* study further established that lovastatin upregulated *Col2* and *SOX9* but downregulated *Col1* expressions in human degenerative NP cells \[[@b23-asj-2018-0257]\]. Reportedly, the mechanism of statins for promoting chondrogenesis of IVD cells is partly mediated by upregulated *BMP-2* through the mevalonate pathway inhibition \[[@b21-asj-2018-0257],[@b22-asj-2018-0257],[@b24-asj-2018-0257]\]. The treatment of IVD cells with *BMP-2* enhances the proteoglycan synthesis and the expression of *Col2* \[[@b23-asj-2018-0257],[@b24-asj-2018-0257],[@b27-asj-2018-0257]\]. This study demonstrated that the expression of *BMP-2* in human MSCs treated only with lovastatin was 10-fold higher than that treated with TGF-β1. In addition, simultaneous or sequential treatments of TGF-β1 and lovastatin could further enhance the *BMP-2* expression in human MSCs. Nevertheless, the expression levels of key ECM elements, such as *Col2* and proteoglycans, were not compatible as *BMP-2*. These findings further corroborated our previous observations that the impact of lovastatin on NP cells or IVDs might not be entirely attributed to the *BMP-2* cascade \[[@b24-asj-2018-0257]\].

For the mRNA profiles of treated MSCs, the upregulation in *AGC* and the suppression in *Col2* were most significant in the group treated with lovastatin only. Conversely, simultaneous or sequential treatments of TGF-β1 and lovastatin exhibited fewer effects. However, the modulation of the *Col2* expression was most prominent in the group with the sequential treatment of TGF-β1 and lovastatin; this promotional phenomenon was compatible with enhancements of the *SOX9* expression. In the immunohistochemical studies, productions of *AGC*, *Col2*, and S-100 protein were compatible in all three groups treated with lovastatin. The discrepancy between mRNA expressions and immunohistochemical studies could be attributed to the treatment duration or other mechanisms. Hence, further studies are warranted to optimize the effects of lovastatin on human MSCs.

In histological studies, the cells in lovastatin-treated groups were less populated than those in the group treated with only TGF-β1. Reportedly, TGF-β1 can induce human MSCs proliferation through the Smad3-dependent nuclear translocation of β-catenin \[[@b28-asj-2018-0257]\]. Likewise, TGF-β1 can also stimulate the NP cell proliferation in a dose- and time-dependent manner \[[@b29-asj-2018-0257]\]. Conversely, lovastatin reportedly decreases the proliferation of human NP cells \[[@b23-asj-2018-0257]\]; this finding was also evident in human MSCs when treated with lovastatin. Notably, this effect might not be desirable, especially when a larger population of cells is anticipated to produce adequate ECM to restore NP tissues. At present, a few modifications to current experimental settings, including higher cell density before lovastatin treatment or shorter time of lovastatin stimulation, are under way.

Conclusions
===========

In this study, lovastatin demonstrated a promising role in inducing human MSCs into NP-like cells. Among all groups, lovastatin-treated MSCs exhibited the highest *AGC* expression and the lowest *Col1* expression. Simultaneous or sequential treatments of TGF-β1 and lovastatin could enhance the *BMP-2* overexpression compared with lovastatin-alone treatment. However, the mRNA expressions of *AGC* and *Col2* were not compatible with the *BMP-2* expression level. In addition, immunohistochemical studies exhibited compatible productions of *AGC*, *Col2*, and S-100 protein in all three groups treated with lovastatin. However, cells in lovastatin-treated groups were less populated than those in the group treated with TGF-β1 alone. Nevertheless, further optimization of treatment duration and combination is essential to achieve better results.

No potential conflict of interest relevant to this article was reported.

Authors thank National Taiwan University Hospital (grant no., NTUH 105-S3112) for financial support.

![Relative expressions of selected genes in each group. Group T: 10 ng/mL TGF-β1; group L: 5 mM lovastatin; group T+L: simultaneous treatment with 10 ng/mL TGF-β1 and 5 M lovastatin; and group T/L: sequential treatment with 10 ng/mL TGF-β1 for 72 hours then 5 M lovastatin for 11 days. *AGC*, *aggrecan*; *Col1*, *collagen type I*; *Col2*, *collagen type II*; *MMP-13*, matrix metalloproteinase-13; TGF-β1, transforming growth factor-beta1.](asj-2018-0257f1){#f1-asj-2018-0257}

![Relative expressions of *BMP-2*. Group T: 10 ng/mL TGF-β1; group L: 5 M lovastatin; group T+L: simultaneous treatment with 10 ng/mL TGF-β1 and 5 M lovastatin; and group T/L: sequential treatment with 10 ng/mL TGF-β1 for 72 hours then 5 mM lovastatin for 11 days. *BMP-2*, *bone morphogenetic protein-2*; TGF-β1, transforming growth factor-beta1.](asj-2018-0257f2){#f2-asj-2018-0257}

![(A--D) Hematoxylin--eosin staining (x100). Mesenchymal stem cells treated with TGF-β1 (group T) display a cobblestone-like shape and a higher cell density. Cells in the L, T+L, and T/L groups display a slightly extending cytoplasm (arrow). Group T: 10 ng/mL TGF-β1; group L: 5 M lovastatin; group T+L: simultaneous treatment with 10 ng/mL TGF-β1 and 5 M lovastatin; and group T/L: sequential treatment with 10 ng/mL TGF-β1 for 72 hours then 5 M lovastatin for 11 days. TGF-β1, transforming growth factor-beta1.](asj-2018-0257f3){#f3-asj-2018-0257}

![(A--D) Immunochemical staining of *AGC* (×100).Pronounced staining is found in lovastatin-treated groups (arrows). However, cells treated with TGF-β1 produce *AGC* weakly. The T+L group exhibit relatively stronger *AGC* staining than the T/L group. Group T: 10 ng/mL TGF-β1; group L: 5 M lovastatin; group T+L: simultaneous treatment with 10 ng/mL TGF-β1 and 5 mM lovastatin; and group T/L: sequential treatment with 10 ng/mL TGF-β1 for 72 hours then 5 M lovastatin for 11 days. *AGC*, *aggrecan*; TGF-β1, transforming growth factor-beta1.](asj-2018-0257f4){#f4-asj-2018-0257}

![(A--D) Immunochemical staining of *Col2* (x100). Pronounced staining is found in lovastatin-treated groups (arrow). However, cells treated with TGF-β1 produce *Col2* weakly. The T+L group exhibit relatively stronger *Col2* staining than the T/L group. Group T: 10 ng/mL TGF-β1; group L: 5 mM lovastatin; group T+L: simultaneous treatment with 10 ng/mL TGF-β1 and 5 M lovastatin; and group T/L: sequential treatment with 10 ng/mL TGF-β1 for 72 hours then 5 M lovastatin for 11 days. *Col2*, *collagen type II*; TGF-β1, transforming growth factor-beta1.](asj-2018-0257f5){#f5-asj-2018-0257}

![(A--D) Immunohistochemical staining of S-100 protein (x100). Pronounced staining is found in lovastatin-treated groups (arrow) but not in the TGF-β1 group. Group T: 10 ng/mL TGF-β1; group L: 5 M lovastatin; group T+L: simultaneous treatment with 10 ng/mL TGF-β1 and 5 M lovastatin; and group T/L: sequential treatment with 10 ng/mL TGF-β1 for 72 hours then 5 M lovastatin for 11 days. TGF-β1, transforming growth factor-beta1.](asj-2018-0257f6){#f6-asj-2018-0257}
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